SYFf2d92a4e71d9417ca4702453ba8e22bdRegistry ID: 2024-513609-29-01|UnknownPhase 4
Loading search results
interventional
N/A
1 country
1
To determine the effectiveness of Botulinum Toxin type A and topical Capsaicin for the treatment of moderate-severe pain in PMS among women who underwent surgery for unilateral breast neoplasia.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 26, 2024
Actual (reported)Pain assessment: Recording of pain intensity using a visual analogue scale (VAS)
Characterization of the predominant pain perception: burning, stabbing pain, sensation of pressure or numbness.
Recording of side effects
Recording of the degree of patient satisfaction
Recording of concomitant analgesic medications
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Qutenza 179 mg cutaneous patch
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CUTANEOUS PATCH
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Qutenza 179 mg cutaneous patch
Named ingredient: Capsaicin
View registry recordHospital Universitario Dr Peset Aleixandre
Valencia, 46017, Spain
M Rosario Beseler Soto
First Submitted
June 26, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.